Ultragenyx FY2023 revenue $434M (+20% YoY); net loss narrows; 2024 guide $500-530M

Ultragenyx Pharmaceutical Inc.

2023-FY EPS reported -$8.25 revenue$434,249,000

Total revenue 2023 $434M (+20% YoY); Crysvita $328M (+17%), Dojolvi $71M (+27%).
Net loss 2023 $607M ($8.25/sh) vs $707M ($10.12) in 2022; Q4 loss $123M ($1.52).
Cash $777M at Dec 31, 2023; 2024 net cash used in ops expected <$400M.
2024 guidance: total revenue $500-530M, Crysvita $375-400M, Dojolvi $75-80M.
Pipeline: DTX401 GSDIa Ph3 data H1 2024; GTX-102 Angelman expansion data H1 2024; setrusumab OI Ph3 enrollment Q1 end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ultragenyx Pharmaceutical Inc. updated its the quarter and full year ended December 31, 2023 guidance (reaffirmed).

Period: the quarter and full year ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 15, 2024, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended December 31, 2023 and the year ended December 31, 2023

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-015856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.